title: Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein.
abstract: Mice overexpressing mutant alpha-synuclein develop a progressive loss of motor function associated with the accumulation of aggregated alpha-synuclein in neurons of the brainstem. Recent reports suggest that tau pathology might also be associated with Parkinson disease (PD) and aggregation of alpha-synuclein. We now report that mice overexpressing A30P alpha-synuclein develop abnormally phosphorylated tau in parallel with the accumulation of aggregated alpha-synuclein. Enhanced phosphorylation of tau occurs only in symptomatic mice that also harbor abundant aggregated alpha-synuclein. The increased phosphorylation of tau occurs at S396/404 and S202 as shown by immunoblotting and immunocytochemical studies with the antibodies PHF-1 and AT8. Neurons that accumulated alpha-synuclein occurred in the dorsal brainstem and did not show strong colocalization with neurons that showed abnormal tau phosphorylation, which largely occurred in the ventral brainstem. Aggregation of alpha-synuclein and phosphorylation of tau are associated with increased levels of phosphorylated c-jun kinase (JNK), which is a stress kinase known to phosphorylate tau protein. These results suggest that alpha-synuclein pathology can stimulate early pathological changes in tau.
authors.affiliation: Department of Pharmacology, Loyola University Medical Center, Maywood, IL 60153, USA.
authors.forename: M
authors.initials: M
authors.lastname: Frasier
authors.forename: M
authors.initials: M
authors.lastname: Walzer
authors.forename: L
authors.initials: L
authors.lastname: McCarthy
authors.forename: D
authors.initials: D
authors.lastname: Magnuson
authors.forename: J M
authors.initials: JM
authors.lastname: Lee
authors.forename: C
authors.initials: C
authors.lastname: Haas
authors.forename: P
authors.initials: P
authors.lastname: Kahle
authors.forename: B
authors.initials: B
authors.lastname: Wolozin
mesh_terms: D000367:Age Factors; D000409:Alanine / Q000235:genetics; D019943:Amino Acid Substitution; D000818:Animals; D000911:Antibodies, Monoclonal / Q000378:metabolism; D015153:Blotting, Western / Q000379:methods; D001921:Brain / Q000166:cytology; D004195:Disease Models, Animal; D005260:Female; D005904:Glial Fibrillary Acidic Protein / Q000276:immunology; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D048031:JNK Mitogen-Activated Protein Kinases / Q000378:metabolism; D048670:MAP Kinase Kinase 4; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D020929:Mitogen-Activated Protein Kinase Kinases / Q000378:metabolism; D009069:Movement Disorders / Q000209:etiology / Q000235:genetics / Q000378:metabolism*; D009154:Mutation; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism; D010300:Parkinson Disease / Q000150:complications / Q000235:genetics; D010766:Phosphorylation; D011392:Proline / Q000235:genetics; D051843:Synucleins; D051844:alpha-Synuclein; D016875:tau Proteins / Q000378:metabolism*
chemical_list: D000911:Antibodies, Monoclonal; D005904:Glial Fibrillary Acidic Protein; D009419:Nerve Tissue Proteins; C085349:PHF-1 monoclonal antibody; C497604:SNCA protein, human; C497605:Snca protein, mouse; D051843:Synucleins; D051844:alpha-Synuclein; D016875:tau Proteins; D011392:Proline; D048031:JNK Mitogen-Activated Protein Kinases; D048670:MAP Kinase Kinase 4; D020929:Mitogen-Activated Protein Kinase Kinases; D000409:Alanine